VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference
VectivBio Holding AG (Nasdaq: VECT) will have its CEO, Luca Santarelli, participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 1:40 p.m. ET. This event will include one-on-one investor meetings and a live webcast available on the company's website. VectivBio is focused on developing treatments for severe rare conditions, with its lead drug, apraglutide, in Phase 3 trials for short bowel syndrome. The company also addresses inherited metabolic diseases in pediatric populations through its CoMET platform.
- None.
- None.
BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022, at 1:40 p.m. ET. Company management will also be participating in one-on-one investor meetings at the conference.
A live webcast of the fireside chat will be accessible through the Events and Presentations section of VectivBio’s website at www.vectivbio.com. An archived replay of the webcast will be available for 30 days following the presentation.
About VectivBio AG
VectivBio (Nasdaq: VECT) is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Our lead product candidate, apraglutide, is a next-generation GLP-2 analog currently in a global Phase 3 clinical trial for short bowel syndrome with intestinal failure (SBS-IF). It is being developed for a range of rare gastrointestinal diseases where GLP-2 plays a central role in disease pathophysiology, including Acute Graft-Versus-Host Disease (aGVHD).
With the CoMET platform, VectivBio aims to address severe and often fatal Inherited Metabolic Diseases (IMDs) in pediatric populations. IMDs represent a group of genetic disorders in which dysregulated Co-enzyme A (CoA) metabolism is a factor. Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA) and propionic acidemia (PA). Additional targets include urea cycle disorders, fatty acid oxidation disorders, and amino acidopathies.
Learn more at www.vectivbio.com, and follow us on LinkedIn and Twitter.
VectivBio Contacts:
Investors & Media:
ir@vectivbio.com
FAQ
When is the VectivBio fireside chat at the SVB Leerink Conference?
Who will represent VectivBio at the SVB Leerink Conference?
Where can I watch the VectivBio fireside chat?
What is VectivBio's lead product candidate?
What diseases does VectivBio's CoMET platform target?
